{"id":24905,"date":"2025-06-05T15:13:09","date_gmt":"2025-06-05T08:13:09","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=24905"},"modified":"2025-06-05T15:13:09","modified_gmt":"2025-06-05T08:13:09","slug":"tsingke-biotech-participates-in-tides-usa-2025-demonstrates-full-scale-oligonucleotide-synthesis-capabilities","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=24905","title":{"rendered":"Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span>, June 5, 2025 \/PRNewswire\/ &#8212;\u00a0Tsingke Biotech recently participated in <b>TIDES <span class=\"xn-location\">USA<\/span> 2025<\/b>, the leading international event for oligonucleotide and peptide therapeutics, held in <span class=\"xn-location\">San Diego<\/span> from <span class=\"xn-chron\">May 19 to 22<\/span>. As a repeat exhibitor, Tsingke highlighted its integrated &#8220;The Great Gene Factory&#8221; model, offering precision synthesis solutions from early discovery to large-scale manufacturing.<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2703094\/TidesUSA_Photo.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2703094\/TidesUSA_Photo.jpg?p=medium600\" title=\"\" alt=\"\" \/><\/a><br \/><span><\/span><\/p>\n<\/div>\n<p>During the exhibition, Tsingke showcased its core offerings including:<\/p>\n<ul type=\"disc\">\n<li>End-to-End synthesis tools, such as the Syn-HCY Series (12P\/192P\/<span class=\"xn-money\">768B<\/span>), delivering high-throughput oligo production for CRISPR, IVD, and research needs<\/li>\n<li>GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity<\/li>\n<li>Application coverage across ASO\/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes<\/li>\n<li>Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency<\/li>\n<\/ul>\n<p>Visitors were particularly impressed by Tsingke&#8217;s automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company&#8217;s ability to integrate <b>reagents, instruments, and services<\/b> into a unified platform drew significant attention from pharmaceutical and biotech partners.<\/p>\n<p>Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis.<\/p>\n<p>For inquiries or collaboration, please contact us at <a href=\"mailto:info@tsingke.com\" target=\"_blank\" rel=\"nofollow\">market@tsingke.com<\/a><\/p>\n<p>Visit: <a href=\"http:\/\/www.tsingke.com\/\" target=\"_blank\" rel=\"nofollow\">www.tsingke.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span>, June 5, 2025 \/PRNewswire\/ &#8212;\u00a0Tsingke Biotech recently participated in <b>TIDES <span class=\"xn-location\">USA<\/span> 2025<\/b>, the leading international event for oligonucleotide and peptide therapeutics, held in <span class=\"xn-location\">San Diego<\/span> from <span class=\"xn-chron\">May 19 to 22<\/span>. As a repeat exhibitor, Tsingke highlighted its integrated &#8220;The Great Gene Factory&#8221; model, offering precision synthesis solutions from early discovery to large-scale manufacturing.<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p><a href=\"https:\/\/mma.prnasia.com\/media2\/2703094\/TidesUSA_Photo.html\" target=\"_blank\" rel=\"nofollow\"><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2703094\/TidesUSA_Photo.jpg?p=medium600\" title=\"\" alt=\"\" \/><\/a><br \/><span><\/span><\/p>\n<\/div>\n<p>During the exhibition, Tsingke showcased its core offerings including:<\/p>\n<ul type=\"disc\">\n<li>End-to-End synthesis tools, such as the Syn-HCY Series (12P\/192P\/<span class=\"xn-money\">768B<\/span>), delivering high-throughput oligo production for CRISPR, IVD, and research needs<\/li>\n<li>GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity<\/li>\n<li>Application coverage across ASO\/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes<\/li>\n<li>Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency<\/li>\n<\/ul>\n<p>Visitors were particularly impressed by Tsingke&#8217;s automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company&#8217;s ability to integrate <b>reagents, instruments, and services<\/b> into a unified platform drew significant attention from pharmaceutical and biotech partners.<\/p>\n<p>Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis.<\/p>\n<p>For inquiries or collaboration, please contact us at <a href=\"mailto:info@tsingke.com\" target=\"_blank\" rel=\"nofollow\">market@tsingke.com<\/a><\/p>\n<p>Visit: <a href=\"http:\/\/www.tsingke.com\/\" target=\"_blank\" rel=\"nofollow\">www.tsingke.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">  <\/div>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-24905","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24905"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24905\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}